Study: Smart Medicine can stop developing fatty liver disease and reduce fibrosis

A groundbreaking international study led by a team from the University of Virginia Community and ‘Kings College London’ revealed that the active substance in the famous slimming medicine ‘Ozempic’ and ‘Wegovy’, known as ‘Simajlotide’, may stop the development of inflammatory fatty liver, and even in contrast to its harmful consequences. The results were published in the New England magazine, to a clinical trial that includes 800 patients from 37 countries. The fatty liver is a common liver disease associated with obesity and type 2 diabetes, as the fat accumulates in the liver, causing infections and scars that can lead to cirrhosis or failure. The disease affects about 15 million Americans, and there is currently only a single drug accredited by the food and drug administration to treat it, making it one of the most important global health challenges. Simaglotide is a drug known for its therapeutic benefits in two main fields, namely the control of blood sugar levels for people with type 2 diabetes and to help patients with obesity lose weight. This medicine works by simulating the work of a natural hormone in the body that helps regulate appetite and slow down the stomach, leading to a longer period of saturation. It also stimulates insulin secretion when blood sugar rises, while glucagon secretion that increases sugar levels. These mechanisms of “samajlotide” have made an effective remedy to manage diabetes and improve metabolic indicators, in addition to helping it with a significant weight loss when using it with a healthy diet and regular exercise. Improving liver health proves the ability of the drug to improve liver health, through various mechanisms that include reducing hepatitis by 63% compared to imaginary therapy, and improving liver fibrosis at 37% of patients. It also contributes to the improvement of weight loss, which reflects positively on metabolism and cardiovascular health, in addition to improving liver function indicators in general, with minor side effects in most cases such as light nausea, making it a promising therapeutic option for non -alcoholic fatty lew pastry. The lead author of the study, Aaron Sanyal, said these results represent a medical penetration because it provides a treatment that improves liver health, and targets the metabolic causes of the disease such as obesity and insulin resistance. Sanyal added that the ‘semagloide’ could become a new treatment option for patients, especially with the association of fatty liver disease with heart and kidney problems. The company that manufactures ‘Simaglotide’ plans to apply for the US Food and Drug Administration this year; To form the remedy formally to treat fatty liver disease. Meanwhile, researchers still follow 1,200 patients up to 5 years; To study the effect of the drug in the long run. The study confirmed that, after its success in the treatment of diabetes and obesity, “semagloide” has been proven to be a medicine with multiple benefit, as it can become the first effective medicine treatment for inflammatory fatty liver patients, giving hope to millions of patients around the world.